Search
AZD 3355
go.drugbank.com/drugs/DB05404InvestigationalAZD 3355 is a reflux inhibitor used for the treatment of Gastroesophageal Reflux Disease. It is developed by AstraZeneca and is currently in phase I/II trials.
Categories: GABA-A Receptor AgonistsXTL-001
go.drugbank.com/drugs/DB05405Investigationalinvestigational monoclonal antibody (MAb) product developed by XTL Biopharmaceuticals to evaluate the safety profile and antiviral activity of the compound in patients chronically infected with hepatitis B
International brands: HepeX-BGTI-2501
go.drugbank.com/drugs/DB05406ExperimentalGTI-2501 is a novel antisense drug which has shown a favorable safety profile in preclinical studies, and in a phase I clinical trial. … The drug is in a phase II clinical trial in combination with docetaxel for the treatment of hormone refractory prostate cancer.
Emricasan
go.drugbank.com/drugs/DB05408InvestigationalIt is developed by Pfizer and made in such a way that it protects liver cells from excessive apoptosis.
VB2-011
go.drugbank.com/drugs/DB05411ExperimentalThis drug includes the parent IgM (H11 IgM) and a recombinant IgG version (H11 IgG). … According to some preclinical studies, it has a potential to inhibit tumour growth in various cancers including lymphoma and melanoma.
Tifuvirtide
go.drugbank.com/drugs/DB05413InvestigationalTifuvirtide is the first members of a new class of anti-HIV drugs which is also called fusion inhibitors. It has received fast-track designation from the FDA and is in Phase I/II clinical testing.
CP-122721
go.drugbank.com/drugs/DB05421ExperimentalCP-122721, neurokinin 1 (NK1) antagonist is developed by Pfizer to treat depression, emesis, and inflammatory diseases including asthma and irritable bowel syndrome.
Categories: Heterocyclic Compounds, 1-RingTalactoferrin alfa
go.drugbank.com/drugs/DB05426InvestigationalTalactoferrin alfa is a novel immunomodulatory 80 kD protein with demonstrated oral anti-tumor properties. Lactoferrin, a protein found in breast milk is developed by Agennix. … It increases body’s immune power and also works as a natural antioxidant, helping to control cell and tissue damage caused by oxidation.
IDD-3
go.drugbank.com/drugs/DB05427ExperimentalIDD-3 is a therapeutic specific immunostimulant developed by IDM Pharma in partnership with sanofi-aventis. It consists of mature dendritic cells loaded with lysates from melanoma tumor cell lines. … It includes Dendritophages that are dendritic cells, a type of specialized immune cells derived from the patient's own white blood cells.
Synonyms: IDD-3VLTS-589
go.drugbank.com/drugs/DB05430InvestigationalVLTS-589 consists of plasmid encoding the angiomatrix protein Del-1 in conjunction with poloxamer 188 for the treatment of peripheral vascular disease.